Economic and health burden of brucellosis in Kazakhstan

Brucellosis is a widespread zoonotic disease considered as an emerging and re‐emerging disease with a resulting threat of public health and animal health. Official reports document an animal incidence in Kazakhstan of about 0.6% per year, and the country still registers high number of human cases annually . The main objective of this paper was to evaluate the distribution and economic impact of brucellosis in Kazakhstan. We analysed human disease incidence data obtained from the Government Sanitary & Epidemiological Service with the aim to estimate the burden of disease in terms of disability‐adjusted life years (DALYs). We also estimated the economic impact in terms of monetary losses. Additionally, we mapped the geographical distribution of the disease throughout Kazakhstan. In total, 1,334 human cases of brucellosis were registered in 2015 in Kazakhstan that resulted in 713 DALYs. Around $21 million was spent on compensation for animals that had to be slaughtered due to brucellosis, and an additional $24 million was spent on testing animals. Animal brucellosis and human brucellosis occur throughout the whole country, some trends of which are reviewed in this paper. We estimated the burden of the disease and explored possible explanation for high human incidence rates. This paper is the first to estimate the human burden of disease and the economic costs in Kazakhstan. Both of these are substantial.     

Estimating direct healthcare costs attributable to laboratory‐confirmed Lyme disease in Ontario,Canada: A population‐based matched cohort study using health administrative data

The objective of this study was to determine healthcare costs attributable to laboratory‐confirmed Lyme disease (LD) from the healthcare payer perspective in Ontario, Canada. A cost‐of‐illness study was conducted for incident LD subjects from 1 January 2006 through 31 December 2013 ascertained from provincial laboratory and reportable disease databases, linked to health administrative data. All LD subjects included were laboratory‐confirmed, according to provincial case definitions. Incident LD subjects were propensity‐score matched to uninfected subjects on age, sex, comorbidities and urban/rural status. We used phase‐of‐care methods to calculate attributable costs for two phases of illness: initial care (≤30 days following “index date”) and continuing care (>30 days after index date to the end of the follow‐up period). A total of 663 incident, confirmed LD subjects were identified from 2006 through 2013. Mean age was 44.2 ± 20.1 years; 339 (51.1%) were female; and 31 (4.7%) were hospitalized ≤30 days after index date. Six hundred fifty‐eight (99.2%) LD subjects were matched to uninfected subjects; mean follow‐up time was 3.3 years. Mean attributable costs per case during the initial care phase and continuing care were $277 (95% CI: $197, $357) and ?$5 (?$27, $17), respectively. Attributable costs per LD subject aged 5–14 years were $440 ($132, $747), greater than the costs observed for other age strata. Expected 1‐year attributable costs were $832, given continuing care costs were negligible. Limitations to our study include estimating costs using a cohort of only laboratory‐confirmed LD cases, introducing selection bias for diagnosed and treated patients who may have a lower risk of developing sequelae. In conclusion, the initial care phase of LD is associated with increased healthcare costs, but without significant costs attributable to LD infection after 30 days. Estimates of costs attributable to LD are important for healthcare resource prioritization and the evaluation of novel interventions.     

Epidemiology and cost of Lyme disease‐related hospitalizations among patients with employer‐sponsored health insurance—United States, 2005–2014

An estimated 300,000 cases of Lyme disease occur in the United States annually. Disseminated Lyme disease may result in carditis, arthritis, facial palsy or meningitis, sometimes requiring hospitalization. We describe the epidemiology and cost of Lyme disease‐related hospitalizations. We analysed 2005–2014 data from the Truven Health Analytics MarketScan Commercial Claims and Encounters Databases to identify inpatient records associated with Lyme disease based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) codes. We estimated the annual number and median cost of Lyme disease‐related hospitalizations in the United States in persons under 65 years of age. Costs were adjusted to reflect 2016 dollars. Of 20,983,165 admission records contained in the inpatient databases during the study period, 2,823 (0.01%) met inclusion criteria for Lyme disease‐related hospitalizations. Over half of the identified records contained an ICD‐9‐CM code for meningitis (n = 614), carditis (n = 429), facial palsy (n = 400) or arthritis (n = 377). Nearly 60% of hospitalized patients were male. The median cost per Lyme disease‐related hospitalization was $11,688 (range: $140–$323,613). The manifestation with the highest median cost per stay was carditis ($17,461), followed by meningitis ($15,177), arthritis ($13,012) and facial palsy ($10,491). Median cost was highest among the 15‐ to 19‐year‐old age group ($12,991). Admissions occurring in January had the highest median cost ($13,777) for all study years. Based on extrapolation to the U.S. population, we estimate that 2,196 Lyme disease‐related hospitalizations in persons under 65 years of age occur annually with an estimated annual cost of $25,826,237. Lyme disease is usually treated in an outpatient setting; however, some patients with Lyme disease require hospitalization, underscoring the need for effective prevention methods to mitigate these serious cases. Information from this analysis can aid economic evaluations of interventions that prevent infection and advances in disease detection.     

Retrospective evaluation of the impact of hypoxemia during thoracic surgery in dogs on outcome: a multicenter analysis of 94 cases

ObjectiveTo investigate the statistical association of severe intraoperative hypoxemia in thoracic surgery with mortality, postoperative hospitalization times and cost of care.Study designRetrospective study.AnimalsDogs that underwent thoracic surgery in three veterinary hospitals between October 1, 2018 and October 1, 2020.MethodsAnesthesia and hospitalization records from 112 dogs were reviewed and 94 cases met inclusion criteria. Recorded data included signalment, disease etiology, pulmonary or extrapulmonary nature of disease, surgical procedure performed, episodes of severe intraoperative hypoxemia defined as a pulse oximetry reading (SpO₂) <90% of 5 minutes or longer duration, survival to discharge, time from extubation to hospital discharge and total invoice cost for clinical visit. Dogs were divided into two groups, those that experienced severe hypoxemia (group A) and those in which SpO₂ reading <90% was not observed throughout the procedure (group B).ResultsGroup A had a greater risk of mortality (odds ratio 10.6, 95% confidence interval 1.9–106.7; p = 0.002), prolonged hospitalization (median 62 hours versus 46 hours; p = 0.035) and more expensive cost of care (median US$10,287 versus $8506; p = 0.056) than group B. No significant difference was found for the type of surgical procedure or pulmonary versus extrapulmonary nature of disease.Conclusions and clinical relevanceSevere intraoperative hypoxemia was statistically associated with an increased risk of mortality and longer postoperative hospitalization times. Although not achieving statistical significance, there was a trend toward increased costs to the client for animals with intraoperative hypoxemia.     

Is the Production of Embryos in Small‐Scale Farming an Economically Feasible Enterprise?

The present assay attempts to evaluate the feasibility of using embryo transfer in small community farmers by in vivo study and by modelling the results obtained. From the total of 59 donor cows, 62.7% responded to treatment, with a significant difference (p = 0.002) in the percentage of the response between breeds, being 90.5% (19/21) in Holstein and 47.4% (18/38) in Brahman. A total of 283 embryos were graded as transferable, while 141 as non‐transferable, without difference in the percentage of transferable embryo by breed (p = 0.18). The mean of transferable embryos graded as class I and II was not different between Holstein and Brahman (p = 0.96 and p = 0.92, respectively); besides, no differences were observed in the other grades (non‐transferable). The highest difference in costs, regardless of its quality by breed, was seen in the lower levels of probable fertility of the embryo transferred, even reaching several hundred dollars. When modelling the expected costs for embryo produced and transferred, values can reach nearly $2000.00 when the probable fertility is only 10%. However, when the probable fertility was 60%, embryo cost was close to $300.00. This technology seems to be viable on average or high‐scale systems, having a superovulatory response between 60 and 80% with 4–6 transferrable embryos. Yet, in small‐scale farming, due to the reduced number of donors and/or recipients, the costs surpass the economical feasibility of the technique.     

Stochastic modelling of direct costs of pancreas disease (PD) in Norwegian farmed Atlantic salmon (Salmo salar L.)

An economic model for estimating the direct costs of disease in industrial aquaculture was developed to include the following areas: biological losses, extraordinary costs, costs of treatment, costs of prevention and insurance pay-out. Direct costs of a pancreas disease (PD) outbreak in Norwegian farmed Atlantic salmon were estimated in the model, using probability distributions for the biological losses and expenditures associated with the disease. The biological effects of PD on mortality, growth, feed conversion and carcass quality and their correlations, together with costs of prevention were established using elicited data from an expert panel, and combined with basal losses in a control model. Extraordinary costs and costs associated with treatment were collected through a questionnaire sent to staff managing disease outbreaks. Norwegian national statistics for 2007 were used for prices and production costs in the model. Direct costs associated with a PD-outbreak in a site stocked with 500,000 smolts (vs. a similar site without the disease) were estimated to NOK (Norwegian kroner) 14.4 million (5% and 95% percentile: 10.5 and 17.8) (NOK = €0.12 or $0.17 for 2007). Production was reduced to 70% (5% and 95% percentile: 57% and 81%) saleable biomass, and at an increased production cost of NOK 6.0 per kg (5% and 95% percentile: 3.5 and 8.7).     

Intercropped oats (<Emphasis Type="Italic">Avena sativa</Emphasis>) - common vetch (<Emphasis Type="Italic">Vicia sativa</Emphasis>) silage in the dry season for small-scale dairy systems in the Highlands of Central Mexico

Small-scale dairy systems in the highlands of central Mexico require feeding strategies based on quality home-grown forage that may reduce high concentrate costs. Eight Holstein cows paired by parity and date of calving were used in a split-plot experiment to evaluate supplementing 6 kg DM/cow/d of oat-vetch silage (OVS) in comparison to maize silage (MS) as dry season feeding, for a more intensive use of the land through an oat-vetch catch crop. Cows had 9 h/d access to continuous grazing of perennial ryegrass – white clover pasture and 4 kg/d of commercial concentrate. The 9 week experiment, recorded weekly milk yield and composition, and body condition score and live-weight every fortnight. Milk yield was 20.1 kg/cow/d for OVS and 15.4 for MS (SEM ±2.9, P > 0.05), with no differences for fat or protein content, body condition score, or live-weight (P > 0.05). The economic analysis showed that although feeding costs were higher for OVS, margins were greater than for MS, with feeding cost per litre of $0.21 for MS and $0.16 for OVS. OVS is a viable catch crop after the MS harvest that can substitute MS in the dry season enabling a more intensive use of the land.     

Vesicular stomatitis epidemic in colorado: Clinical observations and financial losses reported by dairymen

The financial impact and clinical expression of vesicular stomatitis in Colorado dairy herds was studied during the 1982 epidemic. A non-random sample of 15 dairy herds was surveyed, 13 of which had clinical cases in lactating cows. These 13 herds represented 2404 cows among which were 378 clinical cases. The dairymen reported a distribution of lesions among the cases as follows: 262 (69.3%) oral only; 87 (23.0%) teat only; 22 (5.8%) both oral and teat and 7 (1.9%) with foot lesions. Herds experiencing primarily oral lesions had an attack rate of 19.8% with an average clinical course of 23.8 days. The attack rate in 2 of the 4 herds with teat lesions was 55.8% and 1.6% in the other 2 herds. Mastitis complicated 72% of the cases with teat lesions.The direct costs resulting from 378 cases of vesticular stomatitis reported by 13 dairymen totaled $95 752, which is an average cost of $253.31 per clinical case. The average cost per case with oral lesions is estimated to be $174.06 in contrast to $568.22 average for cases with teat lesions. The greatest loss was due to cows culled, 36.6% of the total direct costs. Decreased milk production was second with 30.3% of the total.The average decrease in milk production per clinical case was 261.3 kg (576 lbs). Deaths accounted for 11.3% of the loss and the combined costs of drugs, extra labour, veterinary service, weight loss and extra ectoparasite control accounted for 11.9% of the $95 752 total.     

Costs of veterinary services and vaccines/drugs used for prevention and treatment of diseases in 86 Colorado cow-calf operations participating in the National Animal Health Monitoring System (1986-1988)

Eighty-six cow-calf operations involved in the Colorado National Animal Health Monitoring System were monitored for a 12-month period, and data were collected on the incidence, prevention, and costs of disease. The costs of veterinary services and vaccines/drugs used in the treatment and prevention of disease conditions in these beef herds were determined and expressed on a per cow basis. Beef producers in this study spent an average of $2.04 ($0 to $29.88) per cow annually on veterinary services for treatment of disease conditions. The cost of veterinary services was a relatively small percentage (5.4%) of the total mean cost of disease incidence. The reproductive tract disease class was the most costly class in terms of veterinary services for disease treatment ($0.99/cow). Dystocia was the disease condition with the largest veterinary treatment cost. The total mean annual cost of drugs used in the treatment of disease conditions was $1.22/cow. The enteric, miscellaneous, and respiratory tract disease classes had similar mean drug costs for disease treatment and ranged from $0.31 to $0.39/cow. The total mean annual cost of veterinary services for administration of preventive measures in these herds was $1.85/cow ($0 to $12.03). Pregnancy examination, breeding soundness examination in bulls, brucellosis vaccination, pulmonary arterial pressure test, and campylobacteriosis vaccination accounted for over 90% of the money spent for preventive veterinary services. Approximately 60% of the total mean annual disease prevention cost was attributed to the purchase of vaccines/drugs ($6.59/cow).(ABSTRACT TRUNCATED AT 250 WORDS)     

A Retrospective Economic Analysis of the Ontario Red Fox Oral Rabies Vaccination Programme

Ontario initiated a red fox (Vulpes vulpes ) oral rabies vaccination (ORV) programme in 1989. This study utilized a benefit‐cost analysis to determine if this ORV programme was economically worthwhile. Between 1979 and 1989, prior to ORV baiting, the average annual human post‐exposure treatments, positive red fox rabies diagnostic tests and indemnity payments for livestock lost to rabies were 2248, 1861 and $246 809, respectively. After baiting, from 1990 to 2000, a 35%, 66% and 41% decrease in post‐exposure treatments, animal rabies tests and indemnity payments was observed, respectively. These reductions were viewed as benefits of the ORV programme, whereas total costs were those associated with ORV baiting. Multiple techniques were used to estimate four different benefit streams and the total estimated benefits ranged from $35 486 316 to $98 413 217. The annual mean ORV programme cost was $6 447 720, with total programme costs of $77 372 637. The average benefit‐cost ratios over the analysis period were .49, 1.06, 1.27 and 1.36, indicating overall programme efficiency in three of the four conservative scenarios.     

Veterinary and nonveterinary costs of disease in 29 California dairies participating in the National Animal Health Monitoring System from 1988 to 1989

Twenty-nine California dairy herds were studied over a 12-month period from 1988 to 1989 as part of the National Animal Health Monitoring System. Monthly interviews administered to dairy producers were used to measure the costs of all health-related expenditures and disease incidence in these herds. Of the total $1,523,558 reported, $1,355,467 (89%) was attributed to cost of disease events and $168,091 (11%) to cost of disease prevention. Most (78%) of the cost of disease events was attributable to death and culling losses. Veterinary services accounted for only $54,099 (4%) of total costs, 64% of which was used for disease prevention, compared with 36% for disease treatment. Udder disease was the most costly category of diseases reported at an average of $49.85/head at risk annually, followed by reproductive problems at $38.05. Through the use of sampling strategies less biased than those used in other surveys, the National Animal Health Monitoring System is designed to provide statistically-valid estimates of disease incidence and costs across broad geographic areas, potentially benefiting all those interested in the economics of livestock diseases in the United States.     

Economics of callipyge lamb production

This paper examines the economic implications of callipyge (CLPG) lamb production. The price, as it relates to competing meats and excess fat, significantly impact lamb demand, and CLPG genetics improves those factors. The CLPG phenotype does not affect number or weight of lambs weaned or postweaning ADG, but it does improve postweaning feed efficiency by approximately 10%; dressing percentage approximately 7.5%; and yields of wholesale leg (11.8%), loin (4.7%), rack (2.5%), and shoulder (2.3%). Total production costs for a 59-kg lamb are 4% lower in CLPG lambs due to improved feed efficiency. Assuming pelt and offal value pays for slaughter costs, the costs of normal (N) and CLPG carcasses are the same as for live lambs, $81 and $78, respectively; but, due to dressing percentage, the N carcass weighs 29.2 kg and the CLPG carcass, 31.4 kg. Thus, carcass costs for N and CLPG lambs are $2.77/kg and $2.49/kg, respectively. Decreased feed costs, combined with increased carcass and primal cut yields for CLPG lambs, lowers the price required to recover meat costs for leg, loin, rack, and shoulder by 19.7, 14.4, 12.6, and 11.9%, respectively. Successful marketing of CLPG loin and rack depends on the use of one of several postharvest tenderization procedures. Moisture-enhanced pork is accepted by consumers and often sells for a premium; and moisture enhancement may be appropriate for CLPG lamb. The meat cost per kilogram (including a $.10 per kilogram treatment cost) of tenderized and moisture-enhanced CLPG leg, loin, rack, and shoulder containing 10% added water and ingredients would be lowered to $2.51, $4.65, $5.34, and $1.85, respectively. That represents a total of a 20.9% reduction in cost-basis price. When expressed on the basis of increased revenue from the additional yield of cuts at a given market price, the value of CLPG and moisture-enhanced CLPG cuts from a 59-kg lamb would be, respectively, 14.2% and 23.4% higher than for N lamb. Industrywide adoption of CLPG could increase intermediate-run U.S. profits by $109 million, but the actual effects of CLPG attributes, such as a visual appeal, lower fat and cholesterol content, and reduced seam fat, on consumer demand need to be quantified. If accepted by packers and consumers, moisture-enhanced CLPG lamb has the potential to decrease the cost of lamb to consumers and increase lamb industry profitability.     

Retrospective comparison of the efficacy of fluconazole or itraconazole for the treatment of systemic blastomycosis in dogs

Background: Itraconazole is recommended for treatment of blastomycosis in dogs. Some evidence suggests that fluconazole might be less hepatotoxic than itraconazole. Objectives: To compare (1) incidence of clinical remission and death; (2) treatment duration; (3) total drug cost; (4) incidence of relapse; and (5) incidence of increased ALT activities in dogs with blastomycosis treated with fluconazole or itraconazole. Animals: One hundred and forty‐four dogs with systemic blastomycosis treated with itraconazole or fluconazole from 1998 to 2008. Methods: Retrospective case review. Information obtained included signalment, body weight, clinical signs, drug regimen, treatment duration, time to clinical remission, and laboratory results. Results: Neither treatment efficacy between fluconazole (75% remission) and itraconazole (90% remission) nor relapse rate (18% for itraconazole, 22% for fluconazole) was significantly different (P= .13, .75, respectively). Treatment duration was significantly longer for fluconazole (median 183 days) than for itraconazole (138 days; P= .001). Costs for fluconazole (median $1,223) were significantly less than for itraconazole ($3,717; P < .001). Incidence of increased ALT activities was not significantly different between groups (17% [3/18] for fluconazole, 26% [6/23] for itraconazole; P= .71). Conclusions: Fluconazole is associated with survival to clinical remission in 75% of dogs with blastomycosis. Although dogs receiving fluconazole were treated longer, drug costs were one‐third those of itraconazole. Hepatotoxicosis, as estimated by increases in serum ALT activity, can be observed with similar incidence for both drugs.     

Financial analysis of a clinical trial comparing simple estrus detection with estrus detection after prostaglandin-based appointment breeding in a commercial dairy herd in California, USA

An economic analysis of the outcomes from a clinical trial on dairy cow reproduction was performed. The trial compared two prospective cohorts from a California dairy herd of 670 cows: (1) a cohort of 56 cows initially treated with prostaglandin-F2 and appointment inseminated at 72 and 96 h post-treatment, followed in 7 days by estrus detection based breeding (PT); (2) a cohort of 53 cows that was managed strictly for estrus detection based breeding (HD). There were no significant differences between the cohorts for days in milk at conception, services per conception, or time to events. The economic analysis consisted of three parts: (1) a partial budget analysis of the two breeding strategies; (2) a deterministic decision analysis of the two practices; (3) a stochastic evaluation of the strategies. Both the deterministic and stochastic analyses used time value of money calculattions PT insemination cost the farm approximately $32 compared with an HD cost of approximately $17. However, the costs of getting the average animal pregnant were approximately respectively. Expected monetary values were $588 and $707 for PT and HD strategies, respectively. The stochastic decision analysis evaluated risks and return over 1000 simulations. It suggested that in 73% of cases an HD strategy will produce expected monetary values $170 more than the PT strategy, in 10% of cases the two will be within 4% in yield, and in 17% the PT strategy will yield $95 more than an HD program. Sensitivity analysis suggested that conception rates to estrus detection based breedings are not likely to alter the decision. However, conception rates to the appointment breeding program in conjunction with the elapsed time postpartum when the decision to breed is implemented and estrus detection rates can cause the PT strategy to be optimal. Situations where this might occur are discussed.     

The economic impact of clinical transmissible gastroenteritis for swine producers participating in the Missouri mail-in-record program

Economic loss from transmissible gastroenteritis (TGE) was estimated at $0.18 per hog marketed for the average Missouri Mail-in-Record swine panel producer in 1978. This cost was $0.19 per hog marketed in 1979. These estimates were averaged for all producers in the record system, those with TGE in their herds as well as TGE-free herds. Estimates were also prepared for those herds with TGE outbreaks. In 1978, the average loss due to TGE for producers who had the disease on their farms was estimated at $1.74 per hog marketed, or 18% of the average return earned above total production costs. In 1979, this cost was $1.25 per hog marketed, or 13% of the average return earned above total production costs.     

Efficacy of using previously used controlled internal drug release (CIDR) insert on the reproductive performance,hormone profiles and economic measures of sheep

This study was conducted using 120 multiparous Awassi ewes during the breeding season to compare the effects of using previously used controlled internal drug release (CIDR) on the hormone profiles, reproductive performance and economic measures of ewes. Ewes were randomized to receive one of five previously used CIDR (previously used for 6, 12, 18, 24 or 30 days) or the new CIDR as a control for 6 days (CIDR6, CIDR12, CIDR18, CIDR24, CIDR30, and CIDR0 [control], respectively). Blood samples were collected on four occasions, at the time of CIDR insertion, after 3 days of insertion, and at the time of withdrawal and insemination. Serum estradiol (E2) and progesterone (P4) concentrations were measured. Timed insemination was performed 48 hr post‐CIDR withdrawal. Pregnancy was diagnosed by ultrasonography 23 days after insemination and confirmed on day 35. The heat detection rate was significantly (p < 0.05) higher in the CIDR0 and CIDR6 groups than in the CIDR18 and CIDR30 groups. The total pregnancy rate and fecundity were significantly (p < 0.05) higher in the CIDR6 group than in other groups. P4 level was significantly (p < 0.05) higher in the CIDR0 group than in the CIDR30 group at the time of removal. At each time point, the E2 level was significantly (p < 0.05) higher in the CIDR6 group than at the other groups. The total variable cost, total cost, return and net profit were higher in the CIDR6 and CIDR0 groups than in the other groups. In conclusion, although previously used CIDRs are efficient at synchronizing oestrus in ewes, the duration of previously usage significantly affected the reproductive parameters and economic profit. CIDRs previously used for 6 days and new CIDRs provided the highest fertility and fecundity rates, besides return and net profit. Economically, it is not advisable to use CIDRs that previously used for 12 days or more.     

Influence of multi-enzyme preparation supplemented with sodium butyrate on growth performance blood profiles and economic benefit of growing rabbits

The present study was carried out to explore the impacts of dietary supplementation of enzyme mixture with sodium butyrate on the growth performance, carcass traits, blood profile and economic benefit in two breeds of weanling rabbits adapted to survive in Egypt (New Zealand White and Rex). One-hundred and twenty weaned male rabbits (New Zealand White and Rex) of 6 weeks of age and 770.5 ± 20 g body weight were allotted randomly into four groups in a factorial arrangement. The obtained results indicated that there were non-significant differences in all growth performance traits, blood profile and economic parameters due to the breed effect. However, there were significant differences in most of carcass traits due to the breed effect except total giblets and New Zealand White breed showed the highest value of these parameters including dressing % (p < .01), forequarter and loin % (p < .001) and hindquarter % (p < .003) compared with Rex breed counterparts. The effect of the treatment and its interaction with the breed significantly (p < .05) improved body weight gain, feed consumption and carcass traits (percentage of dressing, forequarter, hind quarter and lion). However, final body weight and feed conversion ratio were not significantly influenced. Supplementing a diet with treatment significantly decreased blood triglycerides, cholesterol and the ratio between albumin and globulin (A/G ratio), while increased blood total protein and globulin. Although higher feed cost and total costs in treated groups than control ones in each breed, they showed higher total return and net return. Rex non-treated rabbit breed showed the lowest profitability measures compared with other groups. In conclusion, dietary supplementation of multi-enzyme with sodium butyrate is highly recommended in growing rabbits due to their beneficial effects on the growth performance and profitability.     

Effects of AGRADO® on Growth Performance and Health of Newly Received Feedlot Calves

Two experiments were conducted to determine the effect of an antioxidant (AGRADO®; Solutia Inc., St. Louis, MO) on the growth, gain to feed ratio, and health of receiving calves. In Experiment 1, 96 mixed breed heifer calves (206 ± 1.4 kg initial BW) were purchased at sale barns and delivered as a single group to the research facility near Fayetteville. All heifers were fed a total mixed diet containing 30% cottonseed hulls, 53% cracked corn, and 11% soybean meal for 42 d with either 0 or 150 mg AGRADO®/kg diet. Fewer (P<0.05) of the heifers fed supplemental AGRADO® were treated for respiratory disease (73% vs 83%), and medication cost was lower (P<0.05) for heifers fed supplemental AGRADO ($6.33 vs $9.49 per pen). Supplemental AGRADO® did not affect (P>0.10) ADG, daily feed intake, and gain to feed ratio. In Experiment 2, 86 bull and steer calves (237 ± 2.2 kg initial BW) were managed and fed as in Experiment 1 for a 41-d study. In this trial, supplemental AGRADO® had no significant effect on the number of sick calves or medication costs, but gain to feed ratio was improved (P<0.05) during the first 28 d of the trial. These results indicate that supplemental AGRADO® may improve the health or growth performance of newly received feedlot cattle.     

Effects of rumen‐protected methionine on milk production in early lactation dairy cattle fed with a diet containing 14.5% crude protein

We evaluated the influence on milk production of feeding early lactation cows a diet that included 14.5% crude protein (CP) and that did not meet methionine (Met) requirements or that met them by supplying rumen‐protected Met (RPMet). Thirty‐nine multiparous Holstein cows were allocated into two groups. For 15 weeks after calving, each group was fed one of the two total mixed rations, Control (n = 20) or Treatment (n = 19). The Treatment group received added RPMet at 0.034% (8 g/day) of the Control diet on dry matter basis. The adequacies of Met for the Control and Treatment groups were 96% and 106%, respectively, and for other amino acids, >110%. The CP level (14.5%) was 1 percentage point lower than that recommended by the Japanese Feeding Standard (2006). No between‐group differences were found in milk yield (40 kg/day), milk composition, plasma profile, rumen fermentation, nitrogen balance, or cow health. Met intake and the amount of rumen‐undegradable feed Met were higher in the Treatment group (p < 0.05). Microbial Met and total metabolizable Met did not differ between groups. Supplying RPMet in a 14.5% CP diet during early lactation did not dramatically affect milk production, because the amount of total metabolizable Met was unchanged.     

An economic analysis of hyperketonemia testing and propylene glycol treatment strategies in early lactation dairy cattle

The purpose was to develop stochastic economic models which address variation in disease risks and costs in order to evaluate different simulated on-farm testing and propylene glycol (PG) treatment strategies based on herd hyperketonemia (HYK) incidence during the first 30 DIM. Data used in model development concerning the difference in health and production consequences between HYK and non-ketotic cows were based on results from 10 studies representing over 13,000 cows from 833 dairy farms in North America, Canada, and Europe. Inputs for PG associated variables were based on a large field trial using cows from 4 free-stall dairy herds (2 in New York and 2 in Wisconsin). Four simulated on-farm testing and treatment strategies were analyzed at herd HYK incidences ranging from 5% to 80% and included: 1) treating all cows with 5 d of PG starting at 5 DIM, 2) testing all cows for HYK 1 day per week (e.g. Mondays) from 3 to 16 DIM and treating all positive cows with 5 d of oral PG, 3) testing all cows for HYK 2 days per week (e.g. Mondays and Thursdays) from 3 to 9 DIM and treating all positive cows with 5 d of oral PG, and 4) testing all cows for HYK 3 days per week (e.g. Mondays, Wednesdays, and Fridays) from 3 to 16 DIM and treating all positive cows with 5 d of oral PG. Cost-benefit analysis included the costs associated with labor to test cows, β-hydroxybutyrate test strips, labor to treat cows, PG, and the associated gain in milk production, decrease in DA and early removal risks of PG treated HYK positive cows compared to non-treated HYK positive cows. Stochastic models were developed to account for variability in the distribution of input variables. Per 100 fresh cows in a herd with an HYK incidence of 40%, the mean economic benefits of the 4 different strategies were $1088, $744, $1166, and $760, respectively. Testing cows 2 days per week from 3 to 9 DIM was the most cost-effective strategy for herds with HYK incidences between 15% and 50%; above 50%, treating all fresh cows with 5 d of PG was the most cost-effective strategy. These results show that for herds similar to those used in model, when herd HYK incidences rise above 25%, almost any HYK testing and treatment protocol will be economically beneficial for the farm.